Literature DB >> 626965

Comparative mammalian metabolism of adriamycin and daunorubicin.

H Loveless, E Arena, R L Felsted, N R Bachur.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626965

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  27 in total

1.  Simulation of the delivery of doxorubicin to hepatoma.

Authors:  Y M Goh; H L Kong; C H Wang
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

2.  Pharmacokinetics of adriamycin, adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver.

Authors:  R Preiss; M Matthias; R Sohr; B Brockmann; H Hüller
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.

Authors:  W Kang; M Weiss
Journal:  Pharm Res       Date:  2001-11       Impact factor: 4.200

Review 4.  A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.

Authors:  R Abraham; R L Basser; M D Green
Journal:  Drug Saf       Date:  1996-12       Impact factor: 5.606

5.  Development of a limited-sampling model for prediction of doxorubicin exposure in dogs.

Authors:  L A Wittenburg; D H Thamm; D L Gustafson
Journal:  Vet Comp Oncol       Date:  2012-07-03       Impact factor: 2.613

6.  Characterization of the Canine Anthracycline-Metabolizing Enzyme Carbonyl Reductase 1 (cbr1) and the Functional Isoform cbr1 V218.

Authors:  Daniel C Ferguson; Qiuying Cheng; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2015-04-27       Impact factor: 3.922

7.  Metabolism of daunorubicin in sensitive and resistant Ehrlich ascites tumor cells. Determination by high pressure liquid chromatography.

Authors:  D Londos-Gagliardi; R Baurain; J Robert; G Aubel-Sadron
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

Review 8.  Clinical pharmacokinetics of idarubicin.

Authors:  J Robert
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

9.  Biological activities of rubidazone.

Authors:  R Maral
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

Review 10.  Epirubicin. Clinical pharmacology and dose-effect relationship.

Authors:  J Robert
Journal:  Drugs       Date:  1993       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.